T-Heart

Addressing an Unmet Clinical Need, T-Heart is developing a novel transcatheter prosthetic heart valve to treat tricuspid regurgitation (TR), a progressive condition in which blood leaks backwards through the tricuspid valve, potentially leading to heart failure and death. Today, patients with Tricuspid Regurgitation remain undertreated and suffer poor quality of life and high mortality. Less than 1% of TR patients are referred to cardiac surgery - involving traumatic thoracotomy and heart-lung bypass machines - because of advanced RV dysfunction or high operative risk (over 10%), leaving the severe TR patients with very limited treatment options.

T-Heart protected innovation aims at immediately reducing the regurgitation with a one step minimally invasive procedure. The T-Heart Tricuspid Valve system includes the T-Heart prosthetic heart valve, a proprietary Delivery System and Valve loader as well as a stabilizer. The T-Heart prosthetic heart valve offers a unique stable and atraumatic anchoring ( IP protected) that will conform to the dilated tricuspid annulus anatomy.

The T-Heart Transcatheter heart valve is protected by two patent families, the first one published and granted in Europe, US, China, Australia, and Japan and Brazil, a second filed in May 2019. A third patent was filed in December 2022